News Eleven seals deal with Roche on eye drug pipeline Deal helps biotech to move on from phase 3 failures
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
